Welcome to Connective Tissue Gene Tests
Connective Tissue Gene Tests (CTGT) specializes in molecular diagnostic testing for inherited genetic disorders.

Browse

Browse our test catalogue by

Single gene testing is available for any listed gene: NGS, Del/Dup, or Comprehensive

CTGT Offers

A large test menu, including Sanger sequencing, Next Generation Sequencing (NGS), and Deletion/Duplication analysis
Prenatal testing for our entire test menu
Unparalleled test sensitivity and accuracy
Expert interpretation of test results supported by superior, proprietary mutation databases
Rapid turn-around times: Sanger sequencing 1-2 weeks; Del/Dup 2-3 weeks; NGS 2-4 weeks
Clear and concise reports
Superior service, consultation and support
Advanced technology and innovative, custom-designed software for our NGS panels
Health Network Laboratories Expands Genetic Testing Services with the Acquisition of Connective Tissue Gene Tests, LLC

Allentown, PA (Jan. 14, 2019) - Health Network Laboratories (HNL), a leader in high quality, innovative laboratory medicine services, announced today they have acquired Connective Tissue Gene Tests, LLC (CTGT), an internationally recognized provider of molecular diagnostic testing services for inherited genetic disorders that delivers clinically actionable diagnostic information to its worldwide customer base.

Founded in 2004 by two of the leading researchers in the field, James Hyland, M.D., Ph.D. and Leena Ala-Kokko, M.D., Ph.D., and based in Allentown, Pennsylvania, CTGT has been at the forefront of the constitutional genetic testing field for more than a decade.  The Company uses its proprietary analytic methods, mutation database and technology to provide more than 3,300 unique tests covering over 1,000 genes. Its efficient systems and team of experts enable CTGT to provide concise and definitive results containing meaningful and focused data analysis, rapidly develop and deploy new tests, and offer consistently superior customer service and best-in-industry, turn-around times. 

“CTGT is an important and exciting addition to HNL's diagnostic service portfolio, allowing us to continue building on our heritage of innovation that provides best in class diagnostic services for the physicians and patients we serve,” said Dr. Peter Fisher, President and CEO of HNL.

According to Dr. Jeff Wisotzkey, HNL’s Clinical Lab Director and Scientific Officer, “The acquisition of CTGT will complement HNL's comprehensive clinical genetic laboratory service programs in cancer, infectious disease, perinatal disease and pharmacogenomics by providing intellectual, bioinformatics and technical synergies amongst all the molecular genetic testing laboratories of HNL, and significantly enhance our capabilities in inherited disease diagnostic services.”

“We are excited about the future of CTGT,” said founders Drs. Hyland and Ala-Kokko.  “HNL will benefit from CTGT’s innovative technologies and expertise in genetics.  We are excited about HNL’s synergistic commitment to quality and customer service which has been so important to our clients.”

Operating for over 20 years, HNL is a leader in laboratory medicine that works with more than 10 hospital systems and has over 60 regional patient service centers.  Each year, HNL generates more than 60 million clinical and anatomic pathology results for approximately 3 million patients and 12,000 healthcare providers.

About Health Network Laboratories (HNL)

Headquartered in Allentown, Pa., Health Network Laboratories (HNL) is a leading multiregional, full-service medical laboratory providing testing and related services to physician offices, hospitals, long-term care facilities, employers and industrial accounts. HNL has more than 60 Patient Service Centers located throughout Pennsylvania and New Jersey. Its staff of over 1,000 includes 35 board-certified pathologists and scientific directors and more than 400 certified lab scientists and phlebotomists working together to provide high-quality, advanced diagnostic testing. In 2018, HNL celebrates its 20th year serving the community. Learn more at HNL.com. Follow us on Facebook, Twitter, Vimeo and LinkedIn.

About Connective Tissue Gene Tests, LLC

Founded in 2004 and headquartered in Allentown, PA Connective Tissue Gene Tests (CTGT) is a leading provider of molecular diagnostic testing through genomic technology for inherited genetic disorders that delivers clinically actionable diagnostic information to its worldwide customer base.

Read More
6 New or updated NGS panels

September 27, 2018- Connective Tissue Gene Tests (CTGT) is pleased to announce 6 New or updated NGS panels.

Read More
7 New or updated NGS panels and tests

July 30, 2018- Connective Tissue Gene Tests (CTGT) is pleased to announce 7 New or updated NGS panels and tests.

Read More
22 New or updated NGS panels and tests

July 12, 2018- Connective Tissue Gene Tests (CTGT) is pleased to announce 22 New or updated NGS panels and tests.

Read More
14 New or updated NGS panels and tests

May 31, 2018- Connective Tissue Gene Tests (CTGT) is pleased to announce 14 New or updated NGS panels and tests.   

Read More
NSGC 37th Annual Conference
Read More
17 New or updated NGS panels

May 14, 2018- Connective Tissue Gene Tests (CTGT) is pleased to announce 17 New or updated NGS panels.  

Read More
2018 ACMG Annual Clinical Genetics Meeting
Read More
NSGC 36th Annual Conference
Read More
CONNECTIVE TISSUE GENE TESTS AUTOMATED RESULTS PORTAL
Read More
IMPORTANT NOTICE: Requisition Forms

CTGT's Requisition Forms have changed! Please be sure to use the latest forms from the Requisition Forms page for all orders.

Read More